Disease relevance of Aplodan

• The action of creatinol-O-phosphate on the recovery of cardiac contractility after ischemia was also observed in hearts partially protected with a cardioplegic solution [1].
• When creatinol-O-phosphate was present during hypoxia, in the physiological solution, the recovery of the contraction after reoxygenation (in the absence of the drug) was improved in a dose-dependent manner [1].
• Effects of creatinol O-phosphate on serum enzymes in acute myocardial infarction [2].
• Protective effect of creatinol O-phosphate (COP) on some experimental arrhythmias in vitro and in vivo [3].
• Activity of creatinol O-phosphate on persistent ventricular premature beats in ischemic heart disease. Double blind clinical trial [4].

High impact information on Aplodan

• When creatinol-O-phosphate was present in the physiological solution before ischemia, the recovery of the contractility after reperfusion was higher than in controls; the presence of creatinol-O-phosphate during reperfusion after ischemia accelerated the recovery of contractility [1].
• It is suggested that creatinol-O-phosphate could exert its cardioprotective effect by an action on anaerobic glycolysis [1].
• Pharmacokinetics of creatinol O-phosphate. Plasma turnover, fate and excretion rate, subcellular distribution in isolated perfused heart and metabolic behaviour [5].
• Protective effect of creatinol O-phosphate (COP) on ventricular fibrillation and death induced by intravenous CaCl2 in mice [6].
• Acute clinical tolerance to N-methyl-N-(beta-hydroxyethyl) guanidine O-phosphate (creatinol O-phosphate, COP) was investigated in volunteer human subjects without heart or renal disease and without other serious illness [7].

Chemical compound and disease context of Aplodan

• The effect of creatinol-O-phosphate (N-methyl-N-(beta-hydroxyethyl)guanidine O-phosphate, creatinolfosfate, Aplodan) pretreatment has been studied on the recovery of contractility of rat isolated heart after hypoxia or ischemia [1].

Biological context of Aplodan

• Creatinol O-phosphate therapy in patients with inadequate coronary circulation. Double-blind clinical trial [8].

Anatomical context of Aplodan

• The size of the reactive area was also reduced but in a manner indicating an action of large creatinol O-phosphate dosages on the microcirculation [9].

Associations of Aplodan with other chemical compounds

• Ionic changes evoked by isoprenaline in rat hearts in vivo and in vitro and their reduction by creatinol O-phosphate [10].

References